≡ Risteys
R13

Documentation Changelog GitHub Contact & Feedback
info icon

This is a non-core endpoint: only basic statistics are computed.

Malignant neoplasm of thymus

DOID Endpoint Browser

C3_THYMUS

thymus neoplasm: A neoplasm that affects the thymus. Representative examples include thymoma and carcinoma.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

None

519972

2. Check conditions

None

519972

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Cause of death: ICD-10 — C37&
  • Cause of death: ICD-9 — 1640
  • Cancer registry: Topography ICD-O-3 — C37
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 3

2 out of 7 registries used, show all original rules.

122

4. Check minimum number of events

None

122

5. Include endpoints

None

122

6. Filter based on genotype QC (FinnGen only)

112

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF9

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 112 53 59
Unadjusted period prevalence (%) 0.02 0.02 0.03
Median age at first event (years) 60.72 59.13 62.15

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
122
Matched controls
1220
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D38.3
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Mediastinum
+∞
69.6
60
*
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
24.8
67.0
58
43
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
31.1
59.3
43
21
C37
ICD-10 Finland
Malignant neoplasm of thymus
+∞
56.8
50
*
D38.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Thymus
+∞
54.3
48
*
GEC24
NOMESCO Finland
Thoracoscopic thymectomy
716.9
50.2
46
*
D15.0
ICD-10 Finland
Benign neoplasm: Thymus
+∞
42.2
38
*
GD1AD
NOMESCO Finland
Thorax CT examination
20.9
41.7
35
23
130
Kela drug reimbursment
Malignant tumour
+∞
35.1
32
*
8580/3-C37.9
ICD-O-3
Thymoma, NOS, of thymus
+∞
35.1
32
*
H02AB02
ATC
dexamethasone; systemic
126.0
34.9
36
*
A03FA01
ATC
metoclopramide; systemic, rectal
9.3
31.2
50
85
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
8.6
30.0
53
100
8582/3-C37.9
ICD-O-3
Thymoma, type AB of thymus
+∞
29.4
27
*
GEC23
NOMESCO Finland
Transsternal thymectomy
+∞
28.2
26
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
8.8
27.8
94
336
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
26.0
24
*
WX408
NOMESCO Finland
General anesthesy, balanced
6.1
22.2
61
172
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
21.5
20
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
21.5
20
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
21.5
20
*
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
+∞
20.4
19
*
JN4BD
NOMESCO Finland
Extensive body CT
18.4
19.9
31
22
B01AB05
ATC
enoxaparin; parenteral
5.3
19.0
62
198
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
8.1
18.9
29
45
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
18.2
17
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
209.1
18.0
18
*
ZXC96
NOMESCO Finland
Robot assisted procedure
209.1
18.0
18
*
R4110
NOMESCO Finland
Physiotherapy
4.8
16.2
56
184
WF002
NOMESCO Finland
Radical radiotherapy
98.0
16.0
17
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
16.0
15
*
GD5BD
NOMESCO Finland
Thorax and upper abdomen combined extensive CT examination of
182.4
15.9
16
*
A04AA02
ATC
granisetron; systemic, transdermal
182.4
15.9
16
*
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
182.4
15.9
16
*
Z51.5
ICD-10 Finland
Palliative care
29.5
15.3
20
8
WX302
NOMESCO Finland
Thoracal epidural anesthesy
29.5
15.3
20
8
TPH07
NOMESCO Finland
Cathetrisation of artery
6.6
15.0
28
53
GEB30
NOMESCO Finland
Mediastinotomy and excision of lesion
+∞
14.9
14
*
L03AA13
ATC
pegfilgrastim; parenteral
169.5
14.8
15
*
N02AA05
ATC
oxycodone; systemic
5.6
14.7
34
79
XX3DW
NOMESCO Finland
Time consuming IT work
13.4
14.3
25
23
N07AA02
ATC
pyridostigmine; systemic
60.8
14.2
16
*
UGC12
NOMESCO Finland
Flexible bronchoscopy
7.7
14.2
22
34
WX402
NOMESCO Finland
General anaesthesia
4.8
14.1
42
121
JN4AD
NOMESCO Finland
Body CT examination
12.8
14.1
25
24
A04AA01
ATC
ondansetron; systemic, rectal
21.4
13.9
20
11
G70.0
ICD-10 Finland
Myasthenia gravis
84.5
13.9
15
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
13.8
13
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
12.7
12
*
108
Kela drug reimbursment
Myasthenia gravis
72.1
11.8
13
*
WZC30
NOMESCO Finland
Teaching
5.0
11.8
30
75
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
11.6
11
*
L01BC06
ATC
capecitabine; oral
+∞
11.6
11
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
11.6
11
*
WZC00
NOMESCO Finland
Treatment plan or consultation
3.8
11.4
54
213
J18.9
ICD-10 Finland
Pneumonia, unspecified
4.0
11.2
43
147
L03AA02
ATC
filgrastim; parenteral
119.9
10.6
11
*
C38.1
ICD-10 Finland
Malignant neoplasm: Anterior mediastinum
+∞
10.6
10
*
8581/3-C37.9
ICD-O-3
Thymoma, type A of thymus
+∞
10.6
10
*
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
10.6
10
*
B01AB04
ATC
dalteparin; parenteral
12.2
10.2
18
17
TPH04
NOMESCO Finland
Cathetrisation of vein
3.8
10.1
40
139
ZXE20
NOMESCO Finland
More than three and less than five hours
4.4
10.0
29
80
D15.2
ICD-10 Finland
Benign neoplasm: Mediastinum
+∞
9.5
9
*
A04AD12
ATC
aprepitant; systemic
+∞
9.5
9
*
WX892
NOMESCO Finland
Monitored bed care
7.5
9.0
21
33
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.2
8.9
52
228
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.1
8.7
20
45
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
8.6
8.5
18
24
ZX090
NOMESCO Finland
Other technic of radiotherapy
96.4
8.5
9
*
8583/3-C37.9
ICD-O-3
Thymoma, type B1 of thymus
+∞
8.4
8
*
L01CB01
ATC
etoposide; systemic
+∞
8.4
8
*
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
+∞
8.4
8
*
8585/3-C37.9
ICD-O-3
Thymoma, type B3 of thymus
+∞
8.4
8
*
GAA31
NOMESCO Finland
Thoracoscopy
+∞
8.4
8
*
GD5AD
NOMESCO Finland
Thorax and upper abdomen combined CT examination of
36.0
8.2
10
*
N03AX16
ATC
[U] pregabalin
3.2
8.1
42
170
ZX120
NOMESCO Finland
Intravenous
7.3
8.1
19
30
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
19.9
7.8
11
6
JN6AD
NOMESCO Finland
CT of torso and neck
27.0
7.7
10
*
R50.9
ICD-10 Finland
Fever, unspecified
3.9
7.6
25
75
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
7.1
7.6
18
29
8070/3-C37.9
ICD-O-3
Squamous cell carcinoma, NOS, of thymus
+∞
7.4
7
*
116
Kela drug reimbursment
Prostate cancer
+∞
7.4
7
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
7.4
7
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
7.4
7
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
7.4
7
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
32.1
7.3
9
*
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
13.1
7.3
12
10
Z2221
NOMESCO Finland
Medical doctor
3.0
7.1
43
189
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
4.8
7.0
17
40
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
10.9
6.7
12
12
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
6.2
6.6
17
31
WW500
NOMESCO Finland
Blood transfusion
15.4
6.5
10
7
ZXE04
NOMESCO Finland
Procedure duration 30 to 39 minutes
6.0
6.4
17
32
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
+∞
6.3
6
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
6.3
6
*
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
+∞
6.3
6
*
GE1CT
NOMESCO Finland
Mediastinal biopsy with CT guidance
+∞
6.3
6
*
ZXD10
NOMESCO Finland
Scheduled procedure
2.6
6.1
55
294
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
7.0
6.1
14
22

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
56
25
40.56
81.37
1.8
1.2
—
—
—
0
0
82
244
8.20
29.80
3.0
1.9
—
—
—
0
0
68
201
6.38
23.75
13.6
4.8
—
—
—
0
0
67
206
6.00
22.09
6.9
3.1
90.28
90.08
%
0.02
67
200
108
512
10.67
21.69
18.0
6.5
3.99
4.15
e9/l
0.39
93
446
99
434
7.80
21.57
11.2
11.6
1.13
1.27
inr
1.03
20
121
29
41
8.97
20.48
11.2
6.6
25.75
24.94
mmol/l
0.46
29
41
94
406
6.73
20.41
12.3
5.5
1.20
1.21
mmol/l
0.49
84
357
30
46
8.32
19.77
9.7
8.2
—
—
—
0
0
43
97
6.30
19.64
11.5
5.5
104.23
104.25
mmol/l
0.01
43
97
29
45
8.14
18.87
15.6
8.7
0.57
0.71
%
1.33
29
45
98
461
6.72
18.61
8.3
5.4
1.72
1.85
e9/l
0.24
82
414
99
470
6.87
18.60
9.8
5.4
0.13
0.20
e9/l
5.75
84
415
97
454
6.55
18.48
8.3
5.3
0.61
0.55
e9/l
1.27
82
396
97
454
6.55
18.48
8.2
5.3
0.04
0.04
e9/l
0.40
82
398
29
47
7.78
18.14
15.4
8.6
1.13
1.59
%
0.99
29
47
93
428
5.93
17.84
8.8
5.7
—
—
—
0
0
33
65
6.59
17.14
15.8
7.2
—
—
—
0
0
40
95
5.78
17.08
12.2
7.3
13.84
11.34
kpa
1.33
40
90
40
95
5.78
17.08
12.1
7.3
5.48
5.26
kpa
0.64
40
89
73
298
4.61
15.73
2.5
1.6
—
—
—
0
0
28
51
6.83
15.61
1.1
1.6
—
—
—
0
0
33
72
5.91
15.32
1.3
1.0
—
—
—
0
0
63
245
4.25
14.17
6.1
2.9
7.40
7.39
ph
—
9
36
25
45
6.73
14.02
2.3
1.8
1.99
2.26
ug/l
0.36
17
33
83
402
4.33
13.50
14.7
7.2
0.00
0.00
e9/l
0.49
67
326
57
216
4.08
13.11
5.6
3.4
—
—
—
0
0
58
238
3.74
11.61
3.3
2.6
0.13
0.31
e6/l
1.23
46
169
36
106
4.40
11.51
1.2
1.5
—
—
—
0
0
42
139
4.08
11.47
1.7
1.7
—
—
—
0
0
57
234
3.70
11.35
3.3
2.4
—
—
—
0
0
41
137
4.00
11.00
3.3
2.7
2.70
3.07
e6/l
0.05
25
68
60
264
3.50
10.58
3.3
2.7
73.02
34.08
e6/l
0.38
48
195
14
6
26.08
10.50
3.0
1.7
26.55
14.01
ug/l
—
14
6
30
88
4.19
9.51
1.2
1.5
—
—
—
0
0
64
310
3.24
9.38
3.9
3.2
89.91
43.85
e6/l
0.28
49
210
24
63
4.50
8.74
2.5
2.1
65.88
66.67
g/l
0.21
24
58
52
234
3.13
8.47
1.4
1.3
—
—
—
0
0
40
156
3.33
8.26
1.8
2.3
577.40
568.24
mosm/kgh2o
0.08
35
127
30
97
3.78
8.24
2.0
2.6
23.54
26.14
%
0.37
30
88
22
57
4.49
8.12
1.7
1.4
0.91
1.18
g/l
0.89
16
52
44
186
3.14
7.90
1.8
2.0
2.92
2.95
mg/l
0.02
39
158
45
205
2.89
6.96
2.1
1.7
1.29
0.91
mg/l
0.77
37
159
9
5
19.24
6.36
2.4
2.0
32.94
46.84
%
—
9
5
6
0
+∞
6.30
2.3
0.0
21.50
—
u/ml
—
6
0
9
6
16.03
6.00
2.3
1.3
403.89
1082.17
e6/l
—
9
6
30
122
2.93
5.58
2.3
1.9
—
—
—
0
0
21
69
3.47
5.53
1.4
1.4
—
—
—
0
0
91
636
2.70
5.48
3.7
3.8
—
—
—
0
0
39
196
2.45
4.73
2.8
3.6
51.88
273.21
ng/l
1.84
32
156
27
118
2.65
4.33
1.3
1.5
—
—
—
0
0
17
57
3.30
4.32
2.8
1.3
—
—
—
0
0
107
865
2.93
3.93
36.9
12.5
15.27
14.76
%
0.48
107
853
11
25
4.73
3.72
2.0
2.2
0.19
1.79
ug/l
1.03
11
25
23
100
2.60
3.71
2.1
2.1
7.87
10.50
umol/l
0.26
23
88
16
58
3.02
3.58
1.1
1.2
19.52
221.81
u/ml
2.08
11
52
18
73
2.72
3.31
5.9
2.6
50.17
63.54
e9/l
0.80
12
56
7
12
6.11
3.06
1.4
1.1
—
—
—
0
0
7
12
6.11
3.06
1.0
1.3
—
—
—
0
0
9
23
4.14
2.83
3.1
2.5
—
—
—
0
0
15
60
2.71
2.83
2.7
5.3
—
—
—
0
0
5
6
8.62
2.77
3.2
6.0
—
—
—
0
0
7
14
5.23
2.77
1.3
1.0
—
—
—
0
0
26
137
2.14
2.72
1.5
1.3
780.00
603.75
titre
—
8
32
90
728
1.90
2.49
4.2
3.6
—
—
—
0
0
6
12
5.20
2.43
1.8
2.1
3.72
2.43
u/ml
—
6
12
45
300
1.79
2.37
2.8
2.3
64.20
72.44
u/l
0.20
45
275
62
455
1.74
2.33
4.1
4.5
0.00
0.00
estimate
-0.00
13
73
6
13
4.79
2.30
1.3
2.2
—
—
—
0
0
6
13
4.79
2.30
1.0
1.0
—
—
—
0
0
15
67
2.41
2.28
1.1
1.3
—
—
—
0
0
36
228
1.82
2.22
2.4
3.0
—
—
—
0
0
31
188
1.87
2.19
1.3
1.2
1112.33
29.25
iu/ml
—
9
57
62
461
1.70
2.18
2.9
3.3
0.00
0.00
estimate
-0.00
13
71
31
189
1.86
2.15
1.8
1.3
2.24
2.48
g/l
0.33
23
111
52
372
1.69
2.09
3.9
3.3
57.58
48.10
ng/l
0.12
42
247
5
10
5.16
2.09
3.0
1.3
—
—
—
0
0
7
20
3.65
2.09
1.3
1.1
—
—
—
0
0
21
113
2.04
2.07
1.3
1.3
—
—
—
0
0
6
16
3.89
1.96
1.5
2.5
26.12
24.56
mmol/l
—
6
16
6
16
3.89
1.96
1.0
1.3
189.33
51.85
pmol/l
—
6
16
116
1069
2.73
1.94
22.2
9.9
—
—
—
0
0
14
66
2.27
1.90
6.4
2.4
3.77
4.16
e9/l
0.30
14
52
15
73
2.20
1.90
3.8
1.8
312.67
373.94
nmol/l
0.78
15
66
8
29
2.88
1.82
1.1
1.1
—
—
—
0
0
33
216
1.72
1.80
3.4
3.4
—
—
—
0
0
59
453
1.59
1.71
2.9
3.3
0.00
0.01
estimate
0.49
12
79
6
19
3.27
1.68
1.3
1.4
—
—
—
0
0
6
19
3.27
1.68
1.0
3.3
—
—
—
0
0
5
14
3.68
1.63
1.4
2.4
4.00
5.04
e9/l
—
5
14
5
14
3.68
1.63
1.0
1.1
—
—
—
0
0
5
14
3.68
1.63
1.4
3.5
63.80
62.14
%
—
5
14
5
15
3.43
1.54
1.6
2.3
4.90
5.12
kpa
—
5
15
5
15
3.43
1.54
1.6
2.3
8.60
8.21
kpa
—
5
15
5
16
3.21
1.45
1.0
1.9
72.00
69.44
%
—
5
16
5
16
3.21
1.45
1.0
1.6
7.44
8.20
kpa
—
5
16
13
67
2.05
1.44
1.8
3.1
—
—
—
0
0
5
18
2.85
1.30
1.0
1.2
—
—
—
0
0
8
35
2.37
1.29
5.4
2.1
—
—
—
0
0
98
1062
0.61
1.27
4.2
5.0
2.76
2.79
mmol/l
0.13
92
989
6
128
0.44
1.25
1.3
1.4
—
—
—
0
0
47
366
1.46
1.18
1.6
1.8
94.17
94.76
pmol/l
0.04
32
174
35
261
1.48
1.09
3.5
3.6
—
—
—
0
0
13
75
1.82
1.07
6.0
3.7
—
—
—
0
0
19
123
1.65
1.07
1.5
1.2
—
—
—
0
0
18
115
1.66
1.07
2.2
1.8
128.88
85.40
ug/g
0.31
18
93
97
1041
0.67
0.94
3.6
4.4
4.74
4.68
mmol/l
0.24
91
969
108
1009
1.61
0.89
4.0
4.2
5.81
5.96
mmol/l
0.78
101
930
6
31
1.98
0.85
2.8
3.6
—
—
—
0
0
11
65
1.76
0.85
2.0
1.5
—
—
—
0
0
30
382
0.72
0.82
2.5
3.0
—
—
—
0
0
13
83
1.63
0.78
1.3
1.3
—
—
—
0
0
9
55
1.69
0.75
4.0
3.1
1.23
1.21
mmol/l
—
9
47
5
24
2.13
0.75
1.4
1.8
—
—
—
0
0
81
728
1.34
0.75
3.3
3.5
14.87
14.76
pmol/l
0.13
75
661
15
101
1.55
0.74
1.5
1.7
—
—
—
0
0
5
25
2.04
0.73
3.0
4.0
3.86
3.96
mmol/l
—
5
25
31
245
1.36
0.69
1.9
2.9
—
—
—
0
0
5
29
1.75
0.64
1.4
1.6
—
—
—
0
0
98
1035
0.73
0.62
3.6
4.3
1.44
1.43
mmol/l
0.04
92
961
8
54
1.51
0.58
1.1
1.3
—
—
—
0
0
6
36
1.70
0.57
1.0
2.1
0.55
0.58
%
—
6
36
23
179
1.35
0.57
1.2
1.3
1.04
9.55
u/ml
—
5
71
6
38
1.61
0.55
1.0
2.1
1.22
1.25
%
—
6
38
9
64
1.44
0.53
2.0
1.4
—
72.50
—
0
6
95
1002
0.77
0.52
3.3
3.9
1.33
1.33
mmol/l
0.01
89
924
29
237
1.29
0.52
3.3
3.4
0.00
0.00
estimate
—
10
71
7
49
1.45
0.47
2.1
2.5
—
—
—
0
0
28
316
0.85
0.26
3.8
3.8
16.24
10.03
mg/mmol
0.31
18
207
0
11
0.00
0.21
0.0
2.5
—
105.64
—
0
11
0
11
0.00
0.21
0.0
2.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
182.29
—
0
11
0
11
0.00
0.21
0.0
2.5
—
4.16
—
0
11
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
24
214
1.15
0.19
3.7
2.4
0.93
0.74
ug/l
0.47
18
130
6
80
0.74
0.16
1.3
1.2
—
—
—
0
0
28
298
0.92
0.10
3.5
3.3
83.69
71.29
mg/l
0.11
21
194
8
75
1.07
0.07
6.1
2.9
—
—
—
0
0
21
205
1.03
0.00
1.1
1.3
0.89
1.04
u/ml
—
7
55
10
105
0.95
0.00
1.7
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
79
0.88
-0.00
1.6
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
293.71
—
0
7
0
5
0.00
-0.00
0.0
1.2
—
82.50
—
0
5
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
12.32
—
0
6
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
8.12
—
0
6
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
153.21
—
0
8
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
5
57
0.87
-0.00
2.4
2.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
9.0
—
0.67
—
0
8
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
10.33
—
0
6
0
5
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.5
—
2225.00
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
5.0
—
0.40
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: C3_THYMUS – Malignant neoplasm of thymus

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).